432 related articles for article (PubMed ID: 28645240)
1. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
Ahmad M; Ahmed OM; Schnepp B; Johnson PR
Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
[TBL] [Abstract][Full Text] [Related]
2. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
Lin A; Balazs AB
Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
[TBL] [Abstract][Full Text] [Related]
3. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
Ahmed Y; Tian M; Gao Y
AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
[TBL] [Abstract][Full Text] [Related]
4. [Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination].
Vzorov AN; Uryvaev LV
Mol Biol (Mosk); 2017; 51(6):945-957. PubMed ID: 29271959
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
Sliepen K; Sanders RW
Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
[TBL] [Abstract][Full Text] [Related]
6. Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.
Ding C; Patel D; Ma Y; Mann JFS; Wu J; Gao Y
Front Immunol; 2021; 12():697683. PubMed ID: 34354709
[TBL] [Abstract][Full Text] [Related]
7. Progress in HIV vaccine development.
Hsu DC; O'Connell RJ
Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
[TBL] [Abstract][Full Text] [Related]
8. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
Girard MP; Picot V; Longuet C; Nabel GJ
Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
[TBL] [Abstract][Full Text] [Related]
9. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
[TBL] [Abstract][Full Text] [Related]
10. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
Brady JM; Baltimore D; Balazs AB
Immunol Rev; 2017 Jan; 275(1):324-333. PubMed ID: 28133808
[TBL] [Abstract][Full Text] [Related]
11. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
12. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.
Williams WB; Zhang J; Jiang C; Nicely NI; Fera D; Luo K; Moody MA; Liao HX; Alam SM; Kepler TB; Ramesh A; Wiehe K; Holland JA; Bradley T; Vandergrift N; Saunders KO; Parks R; Foulger A; Xia SM; Bonsignori M; Montefiori DC; Louder M; Eaton A; Santra S; Scearce R; Sutherland L; Newman A; Bouton-Verville H; Bowman C; Bomze H; Gao F; Marshall DJ; Whitesides JF; Nie X; Kelsoe G; Reed SG; Fox CB; Clary K; Koutsoukos M; Franco D; Mascola JR; Harrison SC; Haynes BF; Verkoczy L
Nat Commun; 2017 Nov; 8(1):1732. PubMed ID: 29170366
[TBL] [Abstract][Full Text] [Related]
13. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Alt FW; Tian M
Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
[TBL] [Abstract][Full Text] [Related]
14. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
Landais E; Moore PL
Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
[TBL] [Abstract][Full Text] [Related]
15. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
Moore PL; Williamson C; Morris L
Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881
[TBL] [Abstract][Full Text] [Related]
16. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
[TBL] [Abstract][Full Text] [Related]
17. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
[TBL] [Abstract][Full Text] [Related]
18. New concepts in HIV-1 vaccine development.
Stephenson KE; D'Couto HT; Barouch DH
Curr Opin Immunol; 2016 Aug; 41():39-46. PubMed ID: 27268856
[TBL] [Abstract][Full Text] [Related]
19. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
Subbaraman H; Schanz M; Trkola A
Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
[TBL] [Abstract][Full Text] [Related]
20. Antibodies in HIV-1 vaccine development and therapy.
Klein F; Mouquet H; Dosenovic P; Scheid JF; Scharf L; Nussenzweig MC
Science; 2013 Sep; 341(6151):1199-204. PubMed ID: 24031012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
